Advertisement

Detection and Treatment of Children and Adolescents with Dyslipidemia

  • Peter O. Kwiterovich
Chapter
Part of the Contemporary Endocrinology book series (COE)

Abstract

Evidence for a causative relationship between dyslipidemia in children and adolescents and the early lesions of atherosclerosis in young adults is strong and internally consistent. Youth affected with dyslipidemia include those with single gene disorders such as familial hypercholesterolemia (FH), and those with oligogenic disorders such as familial combined hyperlipidemia (FCHL). In large populations of children followed up for several decades, the environmental and biologic contributions of elevated low-density lipoprotein (LDL) and obesity to the dyslipidemic phenotype and early subclinical atherosclerosis are impressive. Universal screening will be required for optimal detection and treatment of dyslipidemia and youth at risk for early atherosclerosis. This chapter provides an in-depth clinical and metabolic paradigm where a spectrum of dyslipidemia can be dissected and treated.

Keywords

Disorders involving abnormal LDL receptor activity Oligogenic dyslipidemia Obesity Disorders of low HDL and high triglycerides Effect of dietary and drug treatment 

References

  1. 1.
    Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Summary Report. Pediatrics. 2011;128(Suppl 5):S213–S56.Google Scholar
  2. 2.
    National Heart Lung and Blood Institute. [Internet] Integrated guidelines for cardiovascular health and risk reduction in children and adolescents. [Updated 2011 December]. http://www.nhlbi.nih.gov/guidelines/cvd_ped/index.htm. Accessed 2 April 2012.
  3. 3.
    Kwiterovich PO Jr, Byrne K. Diagnosis and treatment of dyslipoproteinemias in children and adolescents. In: Radovick S, MacGillivray MH, editors. Pediatric endocrinology: a practical clinical guide. 2nd ed. Springer Science + Business media, Chap. 30.New York. pp 537–566.Google Scholar
  4. 4.
    Kwiterovich PO. Recognition and management of dyslipidemia in children and adolescents. J Clin Endocrinol Metab. 2008;93:4200–9.PubMedGoogle Scholar
  5. 5.
    Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111:1795–803.PubMedCentralPubMedGoogle Scholar
  6. 6.
    Wang Y, Huang Y, Hobbs HH, Cohen JC. Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR. J Lipid Res. 2012;53:1932–43.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Usifo E, Leigh SE, Whittall RA, et al. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet. 2012;76:387–401.PubMedGoogle Scholar
  8. 8.
    Kwiterovich PO Jr, Fredrickson DS, Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974;53:1237–49.PubMedCentralPubMedGoogle Scholar
  9. 9.
    Kwiterovich PO Jr, Barton BA, McMahon RP, Obarzanek E, Hunsberger S, Simons-Morton D, Kimm SY, Friedman LA, Lasser N, Robson A, Lauer R, Stevens V, Van Horn L, Gidding S, Snetselaar L, Hartmuller VW, Greenlick M, Franklin F Jr. Effects of diet and sexual maturation on low-density lipoprotein cholesterol during puberty: the Dietary Intervention Study in Children (DISC). Circulation. 1997;96(8):2526–33.PubMedGoogle Scholar
  10. 10.
    Starc TJ, Belamarich PF, Shea S, et al. Family history fails to identify many children with severe hypercholesterolemia. Am J Dis Child. 1991;145:61–4.PubMedGoogle Scholar
  11. 11.
    Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ. 2007;335(7620):59.Google Scholar
  12. 12.
    De Jongh S, Lilien MR, Bakker HD, Hutten BA, Kastelein JJP, Stroes ESG. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis. 2002;163:193–7.PubMedGoogle Scholar
  13. 13.
    Wiegman A, De Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolemia. Lancet. 2004;363:369–70.PubMedGoogle Scholar
  14. 14.
    Neefjes LA, Ten Kate GJ, Alexia R, et al. Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. 2011;219:721–7.PubMedGoogle Scholar
  15. 15.
    Thompson GR. Recommendations for the use of LDL apheresis HEART-UK LDL Apheresis Working Group. Atherosclerosis. 2008;198:247–55.PubMedGoogle Scholar
  16. 16.
    Schmidt HH, Tietge UJ, Buettner J, et al. Liver transplantation in a subject with familial hypercholesterolemia carrying the homozygous p.W577R LDL-receptor gene mutation. Clin Transplant. 2008;22:180–4.PubMedGoogle Scholar
  17. 17.
    El-Rassi I, Chehab G, Saliba Z, Alawe A, Jebara V. Fatal cardiac atherosclerosis in a child 10 years after liver transplantation: a case report and a review. J Clin Lipidol. 2011;5:329–32.PubMedGoogle Scholar
  18. 18.
    Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.PubMedGoogle Scholar
  19. 19.
    Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148–56.PubMedGoogle Scholar
  20. 20.
    Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40–6.PubMedGoogle Scholar
  21. 21.
    Al-Allaf FA, Coutelle C, Waddington SN, et al. LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. Int Arch Med. 2010;13(3):36.Google Scholar
  22. 22.
    Innerarity TL, Mahley RW, Weisgraber KH, et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res. 1990;31:1337–49.PubMedGoogle Scholar
  23. 23.
    Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4:214–Review.Google Scholar
  24. 24.
    Salen G, von Bergmann K, Lutjohann D, et al. and the Multicenter Sitosterolemia StudyGroup. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation. 2004;109:766–71.Google Scholar
  25. 25.
    Pullinger CR, Eng C, Salen G, et al. Human cholesterol7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest. 2002;110:109–25.PubMedCentralPubMedGoogle Scholar
  26. 26.
    Aslanidis C, Ries S, Fehringer P, et al. Genetic and biochemical evidence that CESD and Wolman disease are distinguished by residual lysosomal acid lipase activity. Genomics. 1996;33:85–93.PubMedGoogle Scholar
  27. 27.
    Goldstein JL, Dana SE, Faust JR, Beaudet AL, Brown MS. Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease. J Biol Chem. 1975;250:8487–595.PubMedGoogle Scholar
  28. 28.
    Ginsberg HN, Le NA, Short MP, Ramakrishnan R, Desnick RJ. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest. 1987;80:1692–7.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Bernstein DL, Hülkova H, Bialer MG, Desnick RJ. Cholesteryl Ester Storage Disease: Review of the Findings in 135 Reported Patients with an Under-Diagnosed Disease. J Hepatol. 2013. (epub).Google Scholar
  30. 30.
    Stein J, Garty BZ, Dror Y, et al. Successful treatment of Wolman disease by unrelated umbilical cord blood transplantation. Eur J Pediatr. 2007;166:663–6.PubMedGoogle Scholar
  31. 31.
    Tolar J, Petryk A, Khan K, et al. Long-term metabolic, endocrine, and neuropsychological outcome of hematopoietic cell transplantation for Wolman disease. Bone Marrow Transplant. 2009;43:21–7.PubMedGoogle Scholar
  32. 32.
    Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544–68.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Nielsen S, Karpe F. Determinants of VLDL-triglycerides production. Curr Opin Lipidol. 2012;23:321–6.PubMedGoogle Scholar
  34. 34.
    Subramanian S, Chait A. Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta. 2011;1821:819–25.PubMedGoogle Scholar
  35. 35.
    Cortner JA, Coates PM, Liacouras CA, Jarvik GP. Familial combined hyperlipidemia in children: clinical expression, metabolic defects, and management. J Pediat. 1993;23:177–84. Review.Google Scholar
  36. 36.
    Juo SH, Beaty TH, Kwiterovich PO Jr. Etiologic heterogeneity of hyperapobetalipoproteinemia (hyperapoB). Results from segregation analysis in families with premature coronary artery disease. Arterioscler Thromb Vasc Biol. 1997;17:2729–36.PubMedGoogle Scholar
  37. 37.
    Kwiterovich P, Beaty T, Bachorik P, Chen J, Franklin F, Georgopoulos L, et al. Pediatric hyperlipoproteinemia: the phenotypic expression of hyperapobetalipoproteinemia in young probands and their parents. Prog Clin Biol Res. 1988;255:89–105.PubMedGoogle Scholar
  38. 38.
    Browers MC, van Greevenbroek MM, Stehouwer CD. The genetics of familial combined hyperlipidaemia. Nat Rev Endocrinol. 2012;8:352–62.Google Scholar
  39. 39.
    Ritchie SK, Murphy EC, Ice C, et al. Universal versus targeted blood cholesterol screening among youth: The CARDIAC Project. Pediatrics. 2010;126:260–5.PubMedGoogle Scholar
  40. 40.
    Lee JC, Lusis AJ, Pajukanta P. Familial combined hyperlipidemia: upstream transcription factor 1 and beyond. Curr Opin Lipidol. 2006;17:101–9.PubMedGoogle Scholar
  41. 41.
    Paglialunga S, Fisette A, Yan Y, et al. Acylation-stimulating protein deficiency and altered adipose tissue in alternative complement pathway knockout mice. Am J Physiol Endocrinol Metab. 2008;294:E521–9.PubMedGoogle Scholar
  42. 42.
    Marcil M, Vu H, Cui W, et al. Identification of a novel C5L2 variant (S323I) in a French Canadian family with familial combined hyperlipemia. Arterioscler Thromb Vasc Biol. 2006;26:1619–25.PubMedGoogle Scholar
  43. 43.
    Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet. 2009;10:109–21.PubMedGoogle Scholar
  44. 44.
    Zamel R, Khan R, Pollex RL, Hegele RA. Abetalipoproteinemia: two case reports and lierature review. Orphanet J Rare Dis. 2008;3:19.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Rouis M, Dugi KA, Previato L, et al. Therapeutic response to medium-chain TG and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome. Arterioscler Thromb Vasc Biol. 1997;17:1400–6.PubMedGoogle Scholar
  46. 46.
    Schonfeld G, Lin X, Yue P. Familial Hypobetalipoproteinemia: genetics and metabolism. Cell Mol Life Sci. 2005;62:1372–8.PubMedGoogle Scholar
  47. 47.
    Musunuru K, Pirrucello JP, Do R, et al. Exon sequencing. ANGPTL 3 mutations and familial combined hypolipidemia. N Eng J Med. 2010;363:2220–7.Google Scholar
  48. 48.
    Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72.PubMedGoogle Scholar
  49. 49.
    Vongsuvanh R, Hooper AJ, Coakley JC, et al. Novel mutations in abetalipoproteinemia and homozygous familial hypobetalipoproteinemia. J Inherit Metab Dis. 2007;30:990.PubMedGoogle Scholar
  50. 50.
    Bouma ME, Beucler P, Aggerbeck Infante LP, Schmitz J. Hypobetalipoproteinemia with accumulation of an apoB like protein in intestinal cells: Immunoenzymatic and biochemical characterization of seven cases of Anderson’s disease. J Clin Invest. 1986;78:398–410.PubMedCentralPubMedGoogle Scholar
  51. 51.
    Peretti N, Sassolas A, Roy CC, et al. Guidelines for the diagnosis and treatment of chylomicron retention disease based on the review of the literature and the experience of two centers. Orphanet J Rare Dis. 2010;5:24–34.PubMedCentralPubMedGoogle Scholar
  52. 52.
    Surendran RP, Visser ME, Heemelaar S, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med. 2012;272:185–96.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Adeyo O, Goulbourne CN, Bensadoun A, et al. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 and the intravascular processing of triglyceride-rich lipoproteins. J Intern Med. 2012;272:528–40.PubMedCentralPubMedGoogle Scholar
  54. 54.
    Sharma V, Ryan RO, Forte TM. Apolipoprotein A-V dependent modulation of plasma triacylglycerol: a puzzlement. Biochim Biophys Acta. 2012;821:795–9.Google Scholar
  55. 55.
    Johansen CT, Hegele RA. Genetic bases of hypertriglyceridemic phenotypes. Curr Opin Lipidol. 2011;22:247–53.PubMedGoogle Scholar
  56. 56.
    Mahley RW, Huang Y, Rall SC Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). J Lipid Res. 1999;40:1933–49.PubMedGoogle Scholar
  57. 57.
    Hegele RA, Little JA, Vezina C. Hepatic lipase deficiency: clinical biochemical and molecular genetic characteristics. Arterioscler Thromb. 1993;13:720–8.PubMedGoogle Scholar
  58. 58.
    Ruel IL, Couture P, Gagne C, Deshaies Y, Simard J, Hegele RA, Lamarche B. Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians. J Lipid Res. 2003;44(8):1508–14. (Epub 1 June 2003).PubMedGoogle Scholar
  59. 59.
    Kwiterovich PO Jr. Clinical relevance of the biochemical, metabolic and genetic factors that influence low density lipoprotein heterogeneity. Am J Card. 2002;90(Suppl 8A):30i-48i.PubMedGoogle Scholar
  60. 60.
    Weissglas-Volkov D, Pajukanta P Genetic causes of high and low serum HDL-cholesterol. J Lipid Res. 2010;51:2032–2057.PubMedCentralPubMedGoogle Scholar
  61. 61.
    Cohen JC, Kiss RS, Pertsemlidis A, et al. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science. 2004;305:869–72.PubMedGoogle Scholar
  62. 62.
    Rader DJ. Molecular regulation of HDL metabolism and function: Implications for novel therapies. J Clin Invest. 2006;116:3090–100.PubMedCentralPubMedGoogle Scholar
  63. 63.
    Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant Apo A-I Milano on coronary atherosclerosis in patients with acute coronary syndromes:a randomized controlled trial. JAMA. 2003;290:2292–300.PubMedGoogle Scholar
  64. 64.
    Brunham LR, Singaraja RR, Hayden MR. Variations on a gene:rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. Annu Rev Nutr. 2006;26:105–2980.PubMedGoogle Scholar
  65. 65.
    Brewer HB, Remaley AT, Neufeld EB, et al. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-densitylipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2004;24:1755–60.PubMedGoogle Scholar
  66. 66.
    Calabresi L, Piscotta L, Costantin A, et al. The molecular basis of lecithin: cholesterol acyltransferase deficiency syndromes. A comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Throm Vasc Biol. 2005;25:1972–8.Google Scholar
  67. 67.
    Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutations in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996;97:2917–23.PubMedCentralPubMedGoogle Scholar
  68. 68.
    Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.PubMedGoogle Scholar
  69. 69.
    Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518–20.PubMedGoogle Scholar
  70. 70.
    Swarnakar S, Temel RE, Connelly MA, Azhar S, Williams DL. Scavenger receptor class B, type I, mediates selective uptake of low density lipoprotein cholesteryl ester. J Biol Chem. 1999;274:29733–9.PubMedGoogle Scholar
  71. 71.
    Rigotti A, Edelman ER, Seifert P, et al. Regulation by adrenocorticopic hormoneof the in vivo expression ofscavenger receptor class B type I (SR-BI), a highdensity lipoprotein receptor, in steroidogenic cells of the murine adrenal gland. J Biol Chem. 1996;271:33545–9.PubMedGoogle Scholar
  72. 72.
    West M, Greason E, Kolmakova A, et al. Scavenger receptor class B type I protein as an independent predictor of HDL cholesterol levels in subjects withhyperalphalipoproteinemia. J Clin Endocrinol Metab. 2009;4:1451–7.Google Scholar
  73. 73.
    Naj AC, West M, Rich SS, et al. Association of scavenger receptor class B type I polymorphismswith subclinical atherosclerosis: Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Genet. 2010;3:47–52.PubMedCentralPubMedGoogle Scholar
  74. 74.
    Edmondson AC, Brown RJ, Kathitesan S, et al. Loss-of-function variants in endothelial lipases are a cause of elevated HDL-C in human. J Clin Invest. 2009;119:1042–50.PubMedCentralPubMedGoogle Scholar
  75. 75.
    Koschinsky ML. Novel insights into Lp (a) physiology and pathogenicity. Cardiovasc Hematol Disord Drug Targets. 2006;6:267–78.PubMedGoogle Scholar
  76. 76.
    Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–28.PubMedGoogle Scholar
  77. 77.
    Nowak-Göttl U, Langer C, Bergs S, Thedieck S, Sträter R, Stoll M. Genetics of hemostasis: differential effects of heritability and household components influencing lipid concentrations and clotting factor levels in 282 pediatric stroke families. Environ Health Perspect. 2008;116:839–43.PubMedCentralPubMedGoogle Scholar
  78. 78.
    American Academy of Pediatrics. National cholesterol education program. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics. 1992;89:525–84.Google Scholar
  79. 79.
    Haney EM, Huffman LH, Bougatsos C, et al. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics. 2007;120:e189–214.PubMedGoogle Scholar
  80. 80.
    Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ 2007;335:599. (Epub 2007 Sep 13).PubMedCentralPubMedGoogle Scholar
  81. 81.
    Morris JK, Wald DS, Wald NJ. The evaluation of cascade testing for familial hypercholesterolemia. Am J Med Genet. 2012;158A:78–84. (Epub 2011 Dec 2).PubMedGoogle Scholar
  82. 82.
    Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007;27:1803–10. (Epub 14 Jun 2007). Review.PubMedGoogle Scholar
  83. 83.
    Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292:331–7.PubMedGoogle Scholar
  84. 84.
    Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007;116:664–8.PubMedGoogle Scholar
  85. 85.
    Centers for Disease Control and Prevention (CDC). Prevalence of abnormal lipid levels among youths—United States, 1999–2006. MMWR Morb Mortal Wkly Rep. 2010;59:29–33.Google Scholar
  86. 86.
    Daniels SR. Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122:198–208. (Review).PubMedGoogle Scholar
  87. 87.
    Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011;365:1876–85.PubMedGoogle Scholar
  88. 88.
    McGill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol. 2000;20:1998–2004.PubMedGoogle Scholar
  89. 89.
    Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338:1650–6.PubMedGoogle Scholar
  90. 90.
    McMahan CA, Gidding SS, Malcom GT, et al. Pathobiological Determinants of Atherosclerosis in Youth risk scores are associated with early and advanced atherosclerosis. Pediatrics. 2006;118:1447–55.PubMedGoogle Scholar
  91. 91.
    Magnussen CG, Venn A, et al. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3 C) Consortium. Circulation. 2010;122:2514–20.PubMedGoogle Scholar
  92. 92.
    Davis PH, Dawson JD, Mahoney LT, Lauer RM. Increased carotid intimal-medial thickness and coronary calcification are related in young and middle-aged adults. The Muscatine study. Circulation. 1999;100:838–42.PubMedGoogle Scholar
  93. 93.
    Hartiala O, Magnussen CG, Kajander S, et al. Adolescence risk factors are predictive of coronary artery calcification at middle age: the cardiovascular risk in young Finns study. J Am Coll Cardiol. 2012;60:1364–70.PubMedGoogle Scholar
  94. 94.
    Frontini MG, Srinivasan SR, Xu JH, Tang R, Bond MG, Berenson G. Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults (The Bogalusa Heart Study). Am J Cardiol. 2007;100:64–8.PubMedGoogle Scholar
  95. 95.
    Ritchie SK, Murphy EC, Ice C, et al. Universal versus targeted blood cholesterol screening among youth: the CARDIAC Project. Pediatrics. 2010;126:260–5.PubMedGoogle Scholar
  96. 96.
    Kwiterovich PO, Gidding SS. Universal screening of cholesterol in children. Clin Cardiol. 2012;35:662–4.PubMedGoogle Scholar
  97. 97.
    Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolemia: a prospective registry study. Eur Heart J. 2008;29:2025–33.Google Scholar
  98. 98.
    Wonderling D, Umans-Eckenhausen MA, Marks D, et al. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. D Semin Vasc Med. 2004;4:97–104.Google Scholar
  99. 99.
    Lavigne JV, Brown KM, Gidding S, et al. A cholesterol-lowering diet does not produce adverse psychological effects in children: three-year results from the dietary intervention study in children. Health Psychol. 1999;18:604–13.PubMedGoogle Scholar
  100. 100.
    Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med. 2003;157:821–7.PubMedGoogle Scholar
  101. 101.
    Janssen I, Katzmarzyk PT, Srinivasan SR, et al. Combined influence of body mass index and waist circumference on coronary artery disease risk factors among children and adolescents. Pediatrics. 2005;115:1623–30.PubMedGoogle Scholar
  102. 102.
    Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362–74.PubMedGoogle Scholar
  103. 103.
    Chen W, Srinivasan SR, Li S, Xu J, Berenson GS. Clustering of long-term trends in metabolic syndrome variables from childhood to adulthood in blacks and whites: the Bogalusa Heart Study. Am J Epidemiol. 2007;166:527–33.PubMedGoogle Scholar
  104. 104.
    Morrison JA, Friedman LA, Wang P. Glueck. CJ Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. J Pediatr. 2008;152:201–6.PubMedGoogle Scholar
  105. 105.
    Morrison JA, Friedman LA, Gray-McGuire C. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics. 2007;120:340–5.PubMedGoogle Scholar
  106. 106.
    Urbina EM, Kieltkya L, Tsai J, Srinivasan SR, Berenson GS. Impact of multiple cardiovascular disease risk factors on brachial artery distensibility in young adults: the Bogalusa Heart Study. Am J Hypertens. 2005;18:767–71.PubMedGoogle Scholar
  107. 107.
    Koskinen J, Magnussen CG, Würtz P, et al. Apolipoprotein B, oxidized low-density lipoprotein, and LDL particle size in predicting the incidence of metabolic syndrome: the Cardiovascular Risk in Young Finns study. Eur J Prev Cardiol. 2012;19:1296–303.PubMedGoogle Scholar
  108. 108.
    Magnussen CG, Koskinen J, Chen W, et al. Pediatric metabolic syndrome predicts adulthood metabolic syndrome, subclinical atherosclerosis, and type 2 diabetes mellitus but is no better than body mass index alone: the Bogalusa Heart Study and the Cardiovascular Risk in Young Finns Study. Circulation. 2010;122:1604–11.PubMedCentralPubMedGoogle Scholar
  109. 109.
    Srinivasan SR, Myers L, Berenson GS. Distribution and correlates of non-high- density lipoprotein cholesterol in children: the Bogalusa Heart Study. Pediatrics. 2002;110:e.Google Scholar
  110. 110.
    Li C, Ford ES, McBride PE, Kwiterovich PO, McCrindle BW, Gidding SS. Non-high-density lipoprotein cholesterol concentration is associated with the metabolic syndrome among US youth aged 12–19 years. J Pediatr. 2011;158:201–7.PubMedGoogle Scholar
  111. 111.
    Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein B and AI distributions in the United States. 1988–1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem. 1997;43:2364–78.PubMedGoogle Scholar
  112. 112.
    Ter Avest E, Sniderman AD, Bredie SJH, Wiegman A, Stalenhoef AFH, de Graaf J. Effect of aging and obesity on the expression of dyslipidaemia in children from families with familial combined hyperlipidemia. Clin Sci. 2007;112:131–9.PubMedGoogle Scholar
  113. 113.
    Freedman DS, Bowman BA, Otvos JD, Srinivasan SR, Berenson GS. Levels and correlates of LDL and VLDL particle sizes among children: the Bogalusa Heart Study. Atherosclerosis. 2000;152:441–9.PubMedGoogle Scholar
  114. 114.
    Freedman DS, Bowman BA, Otvos JD, Srinivasan SR, Berenson GS. Differences in the relation of obesity to serum triacylglycerol and VLDL subclass concentrations between black and white children: the Bogalusa Heart Study. Am J Clin Nutr. 2002;75:827–33.PubMedGoogle Scholar
  115. 115.
    Cali AM, Zern TL, Taksali SE, et al. Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: a perfect proatherogenic state. Diabetes Care. 2007;30:3093–8.PubMedGoogle Scholar
  116. 116.
    Tzou WS, Douglas PS, Srinivasan SR, Chen W, Berenson G, Stein JH. Advanced lipoprotein testing does not improve identification of subclinical atherosclerosis in young adults: the Bogalusa Heart Study. Ann Intern Med. 2005;142:742–50.PubMedGoogle Scholar
  117. 117.
    Kaitosaari T, Rönnemaa T, Raitakari O, et al. Effect of 7-year infancy onset dietary intervention on serum lipoproteins and lipoprotein subclasses in healthy children in the prospective, randomized Special Turku Coronary Risk Factor Intervention Project for Children (STRIP) study. Circulation. 2003;108:672–7.PubMedGoogle Scholar
  118. 118.
    Rask-Nissilä L, Jokinen E, Terho P, et al. Neurological development of 5-year-old children receiving a low-saturated fat, low-cholesterol diet since infancy: a randomized controlled trial. JAMA. 2000;284:993–1000.PubMedGoogle Scholar
  119. 119.
    Kaitosaari T, Rönnemaa T, Viikari J, et al. Low-saturated fat dietary counseling starting in infancy improves insulin sensitivity in 9-year-old healthy children: the Special Turku Coronary Risk Factor Intervention Project for Children (STRIP) study. Diabetes Care. 2006;29:781–5.PubMedGoogle Scholar
  120. 120.
    Raitakari OT, Rönnemaa T, Jä rvisalo MJ, et al. Endothelial function in healthy 11-year-old children after dietary intervention with onset in infancy: the Special Turku Coronary Risk Factor Intervention Project for children (STRIP). Circulation. 2005;112:3786–94.PubMedGoogle Scholar
  121. 121.
    Hakanen M, Lagström H, Kaitosaari T, et el. Development of overweight in an atherosclerosis prevention trial starting in early childhood. The STRIP study. Int J Obes (Lond). 2006;30:618–26.Google Scholar
  122. 122.
    Hakanen M, Lagström H, Pahkala K, et al. Dietary and lifestyle counselling reduces the clustering of overweight-related cardiometabolic risk factors in adolescents. Acta Paediatr. 2010;99:888–95.PubMedGoogle Scholar
  123. 123.
    The DISC Collaborative Research Group. The efficacy and safety of lowering dietary intake of total fat, saturated fat, and cholesterol in children with elevated LDL-cholesterol: the Dietary Intervention Study in Children (DISC). JAMA. 1995;273:1429–35.Google Scholar
  124. 124.
    Kwiterovich PO Jr, Barton BA, McMahon RP, et al. Effects of diet and sexual maturation on low-density lipoprotein cholesterol during puberty: the Dietary Intervention Study in Children (DISC). Circulation. 1997;96:2526–33.PubMedGoogle Scholar
  125. 125.
    Obarzanek E, Hunsberger SA, Van Horn L, et al. Safety of a fat-reduced diet: the Dietary Intervention Study in Children (DISC). Pediatrics. 1997;100:51–9.PubMedGoogle Scholar
  126. 126.
    Simons-Morton DG, Hunsberger SA, Van Horn L, et al. Nutrient intake and blood pressure in children: findings from the Dietary Intervention Study in Children (DISC). Hypertension. 1997;29:930–6.PubMedGoogle Scholar
  127. 127.
    Gylling H, Siimes MA, Miettinen TA. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. J Lipid Res. 1995;36:1807–12.PubMedGoogle Scholar
  128. 128.
    Tammi A, Rönnemaa T, Miettinen TA, et al. Effects of gender, apolipoprotein E phenotype and cholesterol-lowering by plant stanol esters in children: the STRIP study. Special Turku Coronary Risk Factor Intervention. Project. Acta Paediatr. 2002;91:1155–62.PubMedGoogle Scholar
  129. 129.
    Amundsen AL, Ose L, Nenseter MS, Ntanios FY. Plant sterol ester enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia. Am J Clin Nutr. 2002;76:338–44.PubMedGoogle Scholar
  130. 130.
    Kwiterovich PO. The role of fiber in the treatment of hypercholesterolemic children and adolescents. Pediatrics. 1995;96:1005–10.PubMedGoogle Scholar
  131. 131.
    Williams CL, Bollella M, Spark A, Puder D. Soluble fiber enhances the hypocholesterolemic effect of the step I diet in childhood. J Am Coll Nutr. 1995;14:251–7.PubMedGoogle Scholar
  132. 132.
    Dennison BA, Levine DM. Randomized, double-blind, placebo-controlled, two-period crossover clinical trial of psyllium fiber in children with hypercholesterolemia. J Pediatr. 1993;123:24–9.PubMedGoogle Scholar
  133. 133.
    Avis HJ, Hutten RA, Gagne C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010;55:1121–6.PubMedGoogle Scholar
  134. 134.
    van der Graaf A, Cuffe-Jackson C, Vissers MN et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008;52:1421–29.PubMedGoogle Scholar
  135. 135.
    Schectman G, Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies. Implications for treatment. Ann Intern Med. 1996;125:990–1000.PubMedGoogle Scholar
  136. 136.
    van der Graaf A, Nieman MC, Firth JC, Wolmarans KH, Marais AD, deGroot E. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolemia. Acta Paediatr. 2006;95:1461–6.PubMedGoogle Scholar
  137. 137.
    Gaist D, Rodriquez LA, Huerta C, et al. Lipid-altering drugs and risk of myopathy: a population based follow-up study. Epidemiology. 2001;12:565–9.PubMedGoogle Scholar
  138. 138.
    Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol. 2007;99:47C–55C.PubMedGoogle Scholar
  139. 139.
    Tonstad S, Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr. 1996;129:42–9.PubMedGoogle Scholar
  140. 140.
    Liacouras CA, Coates PM, Gallagher PR, Cortner JA. Use of cholestyramine in the treatment of children with familial combined hyperlipidemia. J Pediatr. 1993;122:477–82.PubMedGoogle Scholar
  141. 141.
    Stein EA, Marais AD, Szamosi T, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010;156:231–6.PubMedGoogle Scholar
  142. 142.
    Stein EA, Marais AD, Szamosi T, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010;156:231–6.PubMedGoogle Scholar
  143. 143.
    Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201–4.PubMedGoogle Scholar
  144. 144.
    van der Graaf A, Cuffe-Jackson C, Vissers MN et al (2008) Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008;52:1421–9.PubMedGoogle Scholar
  145. 145.
    Gagne C, Gaudet D, Bruckert E. for the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469–75.PubMedGoogle Scholar
  146. 146.
    Lavigne PM, Karas RHJ. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. Am Coll Cardiol. 2013;61:440–6.Google Scholar
  147. 147.
    Keating GM. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus. Am J Cardiovasc Drugs. 2011;11:227–47.PubMedGoogle Scholar
  148. 148.
    Alemzadh R, Langley G, D’Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50:1457–61.Google Scholar
  149. 149.
    Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107:1–7.Google Scholar
  150. 150.
    Silverstein J, Klingensmith G, Copeland K, et al. American Diabetes Association. Care of children and adolescents with type I diabetes. A statement of the American Diabetes Association. Diabetes Care. 2005;28:186–212.PubMedGoogle Scholar
  151. 151.
    Prescott WA, Streetman DD, Streetman DS. The potential role of HMGCoA reductase inhibitors in pediatric nephrotic syndrome. Ann Pharmacother. 2004;38:2105–14.PubMedGoogle Scholar
  152. 152.
    Guttmann-Bauman I. Approach to adolescent polycystic ovary syndrome (PCOS) in the pediatric endocrine community in the U.S.A. J Pediatr Endocrinol Metab. 2005;18:499–506.PubMedGoogle Scholar
  153. 153.
    Vryonidou A, Papatheodorou A, Tavridou A, et al. Association of hyperandrogenic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:2740–6.Google Scholar

Copyright information

© Humana Press 2015

Authors and Affiliations

  • Peter O. Kwiterovich
    • 1
  1. 1.Johns Hopkins Lipid ClinicThe Johns Hopkins School of MedicineBaltimoreUSA

Personalised recommendations